Mentions:
Nine included trials (Fig. 5) contributed to the combined calculation of this variable. There was significant heterogeneity (Tau2 = 0.07; Chi2 = 36.40, df = 8 [P = 0.0001]; I2 = 78%) among the trials. In the random effects model (SMD, 0.34; 95% CI, 0.11–0.56; z = 2.94; P = 0.003), there was a higher risk of reduced SBMs per week in the placebo group and subsequently the frequency of SBMs per week was higher following the use of 2 mg prucalopride to treat chronic constipation.

Mentions:
Nine included trials (Fig. 5) contributed to the combined calculation of this variable. There was significant heterogeneity (Tau2 = 0.07; Chi2 = 36.40, df = 8 [P = 0.0001]; I2 = 78%) among the trials. In the random effects model (SMD, 0.34; 95% CI, 0.11–0.56; z = 2.94; P = 0.003), there was a higher risk of reduced SBMs per week in the placebo group and subsequently the frequency of SBMs per week was higher following the use of 2 mg prucalopride to treat chronic constipation.